Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. BGI Genomics Co., Ltd.
  6. News
  7. Summary
    300676   CNE100003449

BGI GENOMICS CO., LTD.

(300676)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-09-29
53.33 CNY   -0.09%
09/23Genome Sequencing Machine Maker MGI Tech Joins Consortium to Bid For Salt Dam Project
MT
09/06EU to order Illumina to divest Grail after blocking takeover
RE
08/24BGI Genomics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Illumina offers patent licences to rivals, patent truce with BGI - sources

07/27/2022 | 07:46am EDT
A building on the campus at the world headquarters of Illumina is shown in San Diego

BRUSSELS (Reuters) - Illumina has offered rivals royalty-free global licences for some of its patents and a three-year patent truce with Chinese rival BGI in Europe in a bid to address EU antitrust concerns over its acquisition of Grail, people familiar with the matter said.

The U.S. life sciences company submitted the concessions to the European Commission last week.

They consist of royalty-free global licences to rivals of next-generation sequencing technology and equipment and a pledge not to pursue any patent litigation against BGI in Europe, the sources said.

The EU antitrust watchdog had sought feedback from rivals and customers, giving them until Tuesday to do so, they said.

(Reporting by Foo Yun Chee; editing by Jason Neely)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BGI GENOMICS CO., LTD. -0.09% 53.33 End-of-day quote.-39.26%
ILLUMINA, INC. -1.56% 190.79 Delayed Quote.-49.85%
All news about BGI GENOMICS CO., LTD.
09/23Genome Sequencing Machine Maker MGI Tech Joins Consortium to Bid For Salt Dam Project
MT
09/06EU to order Illumina to divest Grail after blocking takeover
RE
08/24BGI Genomics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/11Wuhan Huada Jinuoyin Biotechnology Co., Ltd. announced that it expects to receive fundi..
CI
07/29BGI Genomics Forms Medical Testing JV With Tibbiyah in Saudi Arabia
MT
07/27Exclusive: EU antitrust regulators likely to block Illumina, Grail deal - sour..
RE
07/27Illumina offers patent licences to rivals, patent truce with BGI - sources
RE
07/18BGI Unit Settles US Lawsuit Involving DNA-Sequencing Technology
MT
07/15Illumina Agrees to Pay BGI Genomics $325 Million in DNA-Sequencing Patent Case Settleme..
MT
06/28BGI Genomics Announces Final Profit Distribution for 2021 payable on 06 July 2022
CI
More news
Financials
Sales 2022 5 834 M 820 M 820 M
Net income 2022 1 035 M 145 M 145 M
Net Debt 2022 - - -
P/E ratio 2022 17,4x
Yield 2022 -
Capitalization 21 861 M 3 073 M 3 073 M
Capi. / Sales 2022 3,75x
Capi. / Sales 2023 3,51x
Nbr of Employees -
Free-Float 51,5%
Chart BGI GENOMICS CO., LTD.
Duration : Period :
BGI Genomics Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BGI GENOMICS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 53,33
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Li Jian Zhao General Manager & Director
Yu Jue Wang Chief Financial & Accounting Officer
Jian Wang Chairman
Si Qi Liu Chairman-Supervisory Board
Yu Hui Wu Independent Director
Sector and Competitors